A Phase 4 interventional study of Pitavastatin 4mg in Severe Renal Impairment, sponsored by Kowa Research Institute, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-08-13.
Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 4 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.
Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 358th largest by enrollment of the 468 interventional ones that give a count, is one of 25 that started in 2009, is one of 44 in phase 4, and was the 148th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–80 · Healthy volunteers
Sanofi · Sites in United States
Ages 18–75 · Healthy volunteers
Hoffmann-La Roche · Sites in United States
Ages 18–85 · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in United States
Ages 18–80 · Healthy volunteers
Kailera · Sites in United States
Ages 18–85 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
553 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 247 · Phase 2 71 · Phase 3 53 · Phase 4 44
First in 1990; this study’s year is marked. 25 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 32 across the 468 interventional studies, 182 across the 82 observational. Of the 464 that completed or were terminated, 169 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
334 of 553 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kowa Research Institute, Inc., one of the names counted as Kowa Company, Ltd.. Under that name alone:
Kowa Research Institute, Inc. is the lead sponsor of 47 studies on the registry; 1 is open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 9 (45%) have results posted.
Kowa Company, Ltd. has 1 study filed under Renal Insufficiency — fewer than ten, so there is no comparison to draw.
22 of the studies in Renal Insufficiency with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT07341516Paris Translational Research Center for Organ TransplantationWorldwide Assessment of Deceased Donor Kidney Utilization | 2026-11 |
| NCT04605679Loma Linda UniversityHepatitis C Virus (HCV) Positive Kidney Grafts in HCV Negative Recipients | 2026-12 |
| NCT07857837ShionogiStudy of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy Controls | 2026-12-04 |
| NCT03099434Johns Hopkins UniversityExpanding Live Donor Kidney Transplantation Through Advocacy Training and Social Media | 2026-12-07 |
Add all 22 to your calendar (.ics) → With an account.
Among the 553 studies in Renal Insufficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 4, multicenter, open label, 1 period study. A total of 16 subjects are planned (8 subjects in Group A and 8 subjects in Group B):
The 2 groups will be comparable in terms of age, gender, and body mass index (BMI); the ranges for comparison will be obtained from the pooled demographic data of the renally impaired subjects. The mean age of Group B will be within 5 years of the mean age of Group A, the mean BMI of Group B will be within 18% of the mean BMI of Group A, and the ratio of men to women in Group B will be the same as in Group A.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with severe renal impairment (glomerular filtration rate \[GFR\] of 15 to 29 mL/min/1.73 m2, inclusive) who are not being treated with hemodialysis
Drug: Pitavastatin 4mg
Healthy subjects (GFR greater than or equal to 90 mL/min/1.73 m2)
Drug: Pitavastatin 4mg
Pitavastatin 4mg single dose
Area Under the Curve From 0 to Tau (AUC 0-t (ng*h/mL))
Area under the curve from start to elimination for Pitavastatin.
Time frame: 48 hours
Number of Participants With Treatment Emergent Adverse Events
Time frame: 3 Days
Study period was from 23 November 2009 to 07 June 2010 All subjects were seen at a medical clinic
| Milestone | Pitavastatin 4mg Renal Impaired | Pitavastatin 4mg Healthy Subjects |
|---|---|---|
| Started | 8 | 8 |
| Completed | 8 | 8 |
| Not completed | 0 | 0 |
Area under the curve from start to elimination for Pitavastatin.
| nanogram hour per milliliter (ng•h/mL) | Pitavastatin 4mg Renal Impaired | Pitavastatin 4mg Healthy Subjects |
|---|---|---|
| Area Under the Curve From 0 to Tau (AUC 0-t (ng*h/mL)) | 175 ± 39 | 145 ± 55 |
| Participants | Pitavastatin 4mg Renal Impaired | Pitavastatin 4mg Healthy Subjects |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events | 3 | 3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pitavastatin 4mg Renal Impaired | — | 0/8 (0%) | 3/8 (37.5%) |
| Pitavastatin 4mg Healthy Subjects | — | 0/8 (0%) | 1/8 (12.5%) |
| Event | Pitavastatin 4mg Renal Impaired | Pitavastatin 4mg Healthy Subjects |
|---|---|---|
| DiarrheaGastrointestinal disorders | 1/8 | 0/8 |
| NauseaGastrointestinal disorders | 1/8 | 0/8 |
| VomitingGastrointestinal disorders | 1/8 | 0/8 |
| FatigueGeneral disorders | 1/8 | 0/8 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/8 | 1/8 |
| PolyuriaRenal and urinary disorders | 1/8 | 0/8 |
| Age, Categorical(Participants) | Pitavastatin 4mg Renal Impaired | Pitavastatin 4mg Healthy Subjects | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 8 | 14 |
| >=65 years | 2 | 0 | 2 |
| Age Continuous(years) | Pitavastatin 4mg Renal Impaired | Pitavastatin 4mg Healthy Subjects | Total |
|---|---|---|---|
| Mean | 54.1 ± 15.41 | 52.0 ± 2.62 | 53.1 ± 10.74 |
| Sex: Female, Male(Participants) | Pitavastatin 4mg Renal Impaired | Pitavastatin 4mg Healthy Subjects | Total |
|---|---|---|---|
| Female | 3 | 3 | 6 |
| Male | 5 | 5 | 10 |
| Region of Enrollment(participants) | Pitavastatin 4mg Renal Impaired | Pitavastatin 4mg Healthy Subjects | Total |
|---|---|---|---|
| United States | 8 | 8 | 16 |
The record gives a start of Dec 2009, a primary completion of Apr 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pitavastatin
Kowa Research Institute, Inc. →